Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : China save search
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
LSTA | $2.79 5.28% 5.02% 9.6K
|
Manufacturing
|
| O: -4.12%
H: 9.77%
C: 3.52%
first pancreatic trial therapeutics china
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2024-03-22 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -4.4%
H: 0.97%
C: -0.73%
eslim-02 antibody anemia trial china
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
KZR | $0.8016 -2.95% -3.04% 420K
|
Health Technology
|
| O: 1.09%
H: 3.74%
C: -1.52%
lupus life approval sciences trial china
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 2.64%
H: 5.48%
C: 3.06%
gc012 biotechnologies lupus treatment clearance application trial china
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Published: 2023-12-13 (Crawled : 00:00) - globenewswire.com
HCM | $18.405 0.85% 0.84% 58K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
renal cell trial advanced china
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
CDTX | News | $11.94 16.49% 14.15% 170K
|
Health Technology
|
| O: -0.68%
H: 1.33%
C: -2.03%
rezafungin trial therapeutics china
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-21 (Crawled : 11:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis positive biopharma trial china
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis biopharma trial china
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
Published: 2023-11-16 (Crawled : 00:00) - biospace.com/
ASND | $143.14 -1.17% -1.18% 230K
|
Health Technology
|
| O: 0.39%
H: 0.71%
C: 0.18%
trial china phase 2
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -3.44%
H: 6.1%
C: 3.66%
xipere macular treatment trial china
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Published: 2023-09-20 (Crawled : 14:00) - biospace.com/
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
|
| O: -0.29%
H: 2.06%
C: 0.29%
dextenza ocular treatment trial therapeutics china
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
Published: 2023-08-08 (Crawled : 12:00) - biospace.com/
PTN | $1.73 -1.14% 0.0% 59K
|
Health Technology
|
| O: 14.68%
H: 11.9%
C: 5.6%
vyleesi pharma pharmaceuticals commercial china study
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
Published: 2023-07-10 (Crawled : 12:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -1.75%
H: 3.57%
C: 1.34%
dermatitis biopharma trial china
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
Published: 2023-06-26 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.06%
H: 0.91%
C: 0.72%
tyvyt tumors collaboration trial china therapy
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
Published: 2023-06-06 (Crawled : 20:00) - globenewswire.com
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: -0.39%
H: 5.49%
C: -3.14%
cancer designation topline trial china therapy results
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published: 2023-06-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.79%
H: 1.08%
C: 0.54%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.02%
H: 1.79%
C: 1.69%
ibi351 erbitux merck germany collaboration trial china therapy
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
Published: 2023-05-30 (Crawled : 17:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.11%
H: 1.95%
C: -0.23%
can108 livmarli global china study phase 2
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
Published: 2023-05-25 (Crawled : 20:00) - globenewswire.com
IVA | $3.28 -0.3% -0.3% 13K
|
Health Technology
|
| O: 2.78%
H: 0.67%
C: -2.71%
approval trial china
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.